Forest, Almirall’s Drug Raises Safety Question, FDA Says

Forest Laboratories Inc. and Almirall SA’s experimental drug to treat breathing complications tied to a common lung disease may be linked to more instances of cardiovascular deaths at higher doses, U.S. regulators said.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.